JNJ 26854165
Alternative Names: JNJ-26854165Latest Information Update: 04 Nov 2017
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Research & Development
- Class Antineoplastics; Benzodiazepinones; Indoles; Pyridines; Small molecules
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-mdm2 inhibitors; Proto-oncogene protein c-mdm2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Non-small cell lung cancer; Prostate cancer; Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO)